Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1988 1
1989 3
1990 2
1991 2
1992 1
1993 1
1994 2
1995 3
1996 1
1997 2
1998 2
1999 2
2000 1
2001 4
2002 3
2003 1
2004 1
2005 1
2006 1
2007 1
2008 2
2009 4
2010 3
2011 4
2012 9
2013 6
2014 9
2015 10
2016 3
2017 7
2018 6
2019 10
2020 4
2021 8
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Staber PB, et al. Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Blood. 2019. PMID: 31292114 Free PMC article. Review.
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidel …
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of nov …
T-cell prolymphocytic leukemia.
Dearden CE. Dearden CE. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S239-43. doi: 10.3816/CLM.2009.s.018. Clin Lymphoma Myeloma. 2009. PMID: 19778847 Review.
T-cell prolymphocytic leukemia is a rare postthymic malignancy with distinctive clinical, morphologic, immunophenotypic, and cytogenetic features. The clinical course is typically aggressive with poor response to conventional chemotherapy and short survival. ...
T-cell prolymphocytic leukemia is a rare postthymic malignancy with distinctive clinical, morphologic, immunophenotypic, and cytogenetic fea …
B and T cell prolymphocytic leukaemia.
Cross M, Dearden C. Cross M, et al. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228. doi: 10.1016/j.beha.2019.06.001. Epub 2019 Jun 6. Best Pract Res Clin Haematol. 2019. PMID: 31585622 Review.
Prolymphocytic leukaemias B-PLL and T-PLL are rare disorders, typically with an aggressive clinical course and poor prognosis. Combining morphology, immunophenotyping, cytogenetic and molecular diagnostics reliably separates B-PLL and T-PLL from one another and othe …
Prolymphocytic leukaemias B-PLL and T-PLL are rare disorders, typically with an aggressive clinical course and poor prognosis. …
Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A, Zhang L, Jain AG, Poovathukaran Babu A, Sokol L, Saeed H, Mo Q, Fan W, Zhang X. Rose A, et al. Am J Hematol. 2023 Jun;98(6):913-921. doi: 10.1002/ajh.26918. Epub 2023 Apr 3. Am J Hematol. 2023. PMID: 36964941
T-cell prolymphocytic leukemia (T-PLL) is a rare, post-thymic T-cell neoplasm with a diverse clinical course. T-PLL is typically associated with a poor prognosis; however, a subset of patients have inactive disease on initial presentation. ...We compared patients wi …
T-cell prolymphocytic leukemia (T-PLL) is a rare, post-thymic T-cell neoplasm with a diverse clinical course. T-PLL is typically asso …
T-cell prolymphocytic leukemia.
Khot A, Dearden C. Khot A, et al. Expert Rev Anticancer Ther. 2009 Mar;9(3):365-71. doi: 10.1586/14737140.9.3.365. Expert Rev Anticancer Ther. 2009. PMID: 19275513 Review.
T-cell prolymphocytic leukemia is a rare post-thymic lymphoid disorder, which has distinctive clinical, morphologic, immunophenotypic and cytogenetic features. It has previously been associated with an aggressive course, poor response to conventional chemotherapy and a sho …
T-cell prolymphocytic leukemia is a rare post-thymic lymphoid disorder, which has distinctive clinical, morphologic, immunophenotypic and cy …
Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S, Fang W. Sun S, et al. Biomed Pharmacother. 2020 Jun;126:110107. doi: 10.1016/j.biopha.2020.110107. Epub 2020 Apr 1. Biomed Pharmacother. 2020. PMID: 32247279 Free article. Review.
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T cell leukemia with aggressive clinical course, poor response to conventional therapies and high mortality rates. ...
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T cell leukemia with aggressive clinical course, poor response to conventiona …
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A, Wanquet A, Maitre E, Cornet E, Troussard X, Aurran-Schleinitz T. Collignon A, et al. Curr Oncol Rep. 2017 Apr;19(4):29. doi: 10.1007/s11912-017-0581-x. Curr Oncol Rep. 2017. PMID: 28324286 Review.
Thanks to reduced intensity conditioning regimens, it has become accessible to a larger number of patients. PLL prognosis remains poor with conventional therapies. However, great advances in the understanding of both T- and B-PLL pathogenesis lead to promising new therapeu …
Thanks to reduced intensity conditioning regimens, it has become accessible to a larger number of patients. PLL prognosis remains poo …
Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.
Tian S, Zhang H, Zhang P, Kalmbach M, Lee JH, Ordog T, Hampel PJ, Call TG, Witzig TE, Kay NE, Klee EW, Slager SL, Yan H, Ding W. Tian S, et al. Sci Rep. 2021 Apr 15;11(1):8318. doi: 10.1038/s41598-021-87890-9. Sci Rep. 2021. PMID: 33859327 Free PMC article.
T cell prolymphocytic leukemia (T-PLL) is a rare disease with aggressive clinical course. Cytogenetic analysis, whole-exome and whole-genome sequencing have identified primary structural alterations in T-PLL, including inversion, translocation and copy number variation. .. …
T cell prolymphocytic leukemia (T-PLL) is a rare disease with aggressive clinical course. Cytogenetic analysis, whole-exome and whole …
Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK, Helgeland L, Liseth K, Micci F, Sandnes M, Russnes HG, Reikvam H. Gjelberg HK, et al. Curr Oncol. 2023 Nov 18;30(11):10007-10018. doi: 10.3390/curroncol30110727. Curr Oncol. 2023. PMID: 37999147 Free PMC article. Review.
The disease typically presents at an advanced stage, with marked leukocytosis, B symptoms, hepatosplenomegaly, and bone marrow failure. It usually follows an aggressive course from presentation, and the prognosis is often considered dismal; the median overall surviv …
The disease typically presents at an advanced stage, with marked leukocytosis, B symptoms, hepatosplenomegaly, and bone marrow failure. It u …
The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia.
Erkeland SJ, Stavast CJ, Schilperoord-Vermeulen J, Dal Collo G, Van de Werken HJG, Leon LG, Van Hoven-Beijen A, Van Zuijen I, Mueller YM, Bindels EM, De Ridder D, Kappers-Klunne MC, Van Lom K, Van der Velden VHJ, Langerak AW. Erkeland SJ, et al. Haematologica. 2022 Jan 1;107(1):143-153. doi: 10.3324/haematol.2020.263756. Haematologica. 2022. PMID: 33596640 Free PMC article.
T-cell prolymphocytic leukemia (T-PLL) is mostly characterized by aberrant expansion of small- to medium-sized prolymphocytes with a mature post-thymic phenotype, high aggressiveness of the disease and poor prognosis. However, T-PLL is more heterogeneous with a wide range …
T-cell prolymphocytic leukemia (T-PLL) is mostly characterized by aberrant expansion of small- to medium-sized prolymphocytes with a mature …
120 results